Evaluation of immunophenotypic markers and clinico-hematological profile in chronic lymphocytic leukemia: implications for prognosis

Bagheri, Marziye; Vosoughi, Tina; Hosseinzadeh, Mehran; Saki, Najmaldin

doi:10.1186/s13104-020-05243-7

Cited by 4 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 as well as, immunophenotypic analysis by flow-cytometry regarded as a gold standard test in confirmation of CLL diagnosis and typically performed in all patients with lymphocytosis. 5 the leukemic cells of CLL have the characteristic immunophenotypic profile including positive expression of CD5, CD19 and CD23, and usually weak expression of CD20, CD22, CD79b, sIg (IgM, IgD) and negative expression of CD10 and FMC7, 9,10 The population's clonality is demonstrated by monoclonal kappa and lambda light chains analysis ,the leukemic cells express either kappa or lambdalight chains. 11 the immunophenotyping of CLL is considered in the specific scoring system for diagnosis of CLL and in the differentiation of CLL from other mature B-cell neoplasms.…”

Section: Introductionmentioning

confidence: 99%

Study of immunophenotypic markers and clinico-hematological findings in chronic lymphocytic leukemia

Mazin Butrous,

Sadiq Muhammad

2023

Zanco J Med Sci

View full text Add to dashboard Cite

Background and objective: Chronic lymphocytic leukemia (CLL) is a clonal, mature B-cell neoplasm, its clinical features, cell morphology, and immunophenotyping are used to establish the diagnosis. Immunophenotyping by flow cytometry is the most accurate procedure for diagnosing CLL, there is no single marker exclusively expressed in CLL, however, a complex of immunophenotypic markers that incorporates several B-cell markers and assists in differentiating CLL from other mature B-cell neoplasms, the expression of these immunophenotypic markers is considered in the specific CLL scoring system (Moreue scoring system).this study aimed to assess the clinico – hematological features and immunophenotypic characteristics of CLL patients and to assess the role of immunophenotyping in the differential diagnosis of CLL. Methods: an observational prospective and retrospective study was carried out at Nanakaly hospital for blood diseases and oncology in Erbil city, Iraq. That was conducted on 100 patients newly diagnosed with mature B cell neoplasm which included 68 cases of CLL and 32 cases with other mature B cell neoplasm (MBN), usinga convenience sampling method. The study period was from the1st of September 2021 to the end of April 2022. An interview questionnaire was used to collect the study data from the patients. Results: The mean of age ± standard deviation of the CLL patients (58.85 ± 10.69) years and (66.2%) was male, The most frequent clinical presentations for CLL cases were fatigue (50%), lymphadenopathy (41.2%), and splenomegaly (41.2%), (50%) of CLL patients had anemia, thrombocytopenia was seen in (32.4%) and leukocytosis was seen (98.5%), all patients had lymphocytosis and (97%) had an absolute B lymphocyte count of more than 5 x109 /L. all the studied CLL patients expressed both CD45 and CD19 markers, the expression of the immunophenotypic markers was as following: CD5 (98.5%), CD23 (97.1%) and CD200 (97.1%), Half of the patients (50%) showed expression of monoclonal lambda light chain, sIgM (4.4%), CD20 (88.2%) and CD43 (54.4%) and CD38 (26.5%). The expression of the following marker had a significant role in the differentiation between CLL and other MBN: CD5, CD23, CD79b, FMC7, sIgM, CD200, and CD43. Conclusion: Our results have shown that the clinical presentations and hematological profile of Iraqi CLL patients were not significantly different from that of previous local and global studies, the distinct immunophenotyping, as well as it has been found that immunophenotyping is a promising method for supporting the clinical and morphological characterization of CLL.

show abstract

Section: Introductionmentioning

confidence: 99%

Study of immunophenotypic markers and clinico-hematological findings in chronic lymphocytic leukemia

Mazin Butrous,

Sadiq Muhammad

2023

Zanco J Med Sci

View full text Add to dashboard Cite

show abstract

A Study of Cytokine patterns of T helper type 1 cytokine (IL-2), T helper type 2 cytokine (IL-6) and Regulatory cytokine (IL-10) in Chronic Lymphocytic Leukemia (CLL) – A Real World Data at a tertiary care center

Tamizhan,

Naithani,

Bains

et al. 2024

Preprint

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) remains a challenging disease to manage due to its heterogeneous nature and the lack of clarity regarding prognostic markers. This study aimed to clarify cytokine behavior in different stages (Binet and Modified Rai staging) and phases of CLL, particularly focusing on T helper cell dynamics, and investigate their potential as prognostic biomarkers. Serum samples from 70 participants were analyzed for levels of cytokines Interleukin IL-2, IL-6, IL-10, and serum beta2 microglobulin using Sandwich ELISA and Chemiluminescence immunoassay methods. Clinical parameters, hematological profiles, and CLL disease stage were documented at baseline. Pearson chi-square, Fisher's exact tests, Mann-Whitney U tests, Kruskal-Wallis tests, and correlation analyses with p-value less than 0.05 were considered statistically significant. In present study, 70 CLL patients were included. Median age recorded as 62 years. The proportion of the disease was 2.45 times higher in males. According to Modified Rai and Binet staging, the study participants were classified into low, moderate, or high risk as 17%, 37%, 46%, and 30%, 26%, and 44%, respectively. The mean levels of IL-2, IL-6, IL-10, and serum beta2 microglobulin were 14.09 pg/ml, 42.92 pg/ml, 43.02 pg/ml, and 6.63 ug/L, respectively. Median levels were 7.23 pg/ml for IL-2, 44.74 pg/ml for IL-6, 31.11 pg/ml for IL-10, and 7.29 ug/L for serum beta2 microglobulin. IL-2 positively correlated with hemoglobin and platelet count but negatively correlated with lymphocyte count and serum LDH levels. Conversely, IL-6, IL-10 and Sβ2M were positively correlated with lymphocyte count and serum LDH levels but negatively correlated with hemoglobin and platelet count with p value of 0.0001. Comparison across Modified Rai and Binet staging revealed decreasing IL-2 levels (range 35.68pg/ml to 3.55mg/ml, p value 0.00001) and increasing IL-6 (15.05pg/ml to 58.95pg/ml, p value 0.03), IL-10 (2.11pg/ml to 76.11pg/ml, p value 0.00001), and Sβ2M values (2.96ug/ml to 8.17ug/ml, p value 0.00001) with disease progression from Low to Intermediate and High risks groups. IL-6 and IL-10 has been found significant positively correlated (p value 0.00001) while IL-2 negatively correlated (p value 0.00001) with Sβ2M levels in the study patients. These findings underscore the complex link between cytokines and CLL progression, with possible implications for prognosis and treatment. Our study found that blood levels of IL-6, IL-10, and Sβ2M rose with CLL progression, as did Interleukin-2 in the early stages of the disease. Furthermore, cytokine levels should be evaluated as a novel clinical prognostic marker for predicting early disease load and an aggressive treatment regimen to improve CLL patients' 5-year survival rates. In the coming years, cytokine levels may play an important role in treatment selection and delivering good treatment-free survival in CLL.

show abstract

The significance of Rai and Binet clinical staging on the survival of chronic lymphocytic leukemia patients in the Kurdistan region of Iraq

Muhammad¹,

Yassin

Shamoon

et al. 2021

Iraqi J Hematol

View full text Add to dashboard Cite

Evaluation of immunophenotypic markers and clinico-hematological profile in chronic lymphocytic leukemia: implications for prognosis

Cited by 4 publications

References 25 publications

Study of immunophenotypic markers and clinico-hematological findings in chronic lymphocytic leukemia

Study of immunophenotypic markers and clinico-hematological findings in chronic lymphocytic leukemia

A Study of Cytokine patterns of T helper type 1 cytokine (IL-2), T helper type 2 cytokine (IL-6) and Regulatory cytokine (IL-10) in Chronic Lymphocytic Leukemia (CLL) – A Real World Data at a tertiary care center

The significance of Rai and Binet clinical staging on the survival of chronic lymphocytic leukemia patients in the Kurdistan region of Iraq

Contact Info

Product

Resources

About